Bolt Biotherapeutics Inc CMC Considerations For In-Human Studies with Drs. Edith Perez And Nathan Ihle Transcript
Welcome to the Business of Biotech. If you've listened to our summer executive sessions, you'll be familiar with Bolt Biotherapeutics. We had a great conversation with Bolt, CEO, Randy Schatzman, about how is keeping the money train rolling despite the disruption of COVID-19.
On today's episode, we're jumping into CMC and patient centricity considerations with two of Dr. Schatzman's brightest stars; doctors Edith Pérez, CMO; and Nathan Ihle, CTO at Bolt. This was a particularly fun and informative episode because it really illustrates the importance of a connection that can be easy to lose that between the technicalities of CMC considerations in preparation for first-in-human studies and the patient first responsibilities that make the Chief Medical Officer role so important for clinical stage biotechs. Let's give it a listen.
In this episode of the Business of Biotech, I am thrilled to sit down with two of Bolt Biotherapeutics' finest new in both cases, stars, Dr. Edith Pérez, who just joined the company as Chief Medical Officer; and Dr.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
